Alessandro Armuzzi
Appearances
- DateMay 20, 2024Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
Presenter
Icahn School of Medicine, Mount Sinai - DateMay 21, 2024BACKGROUND: Risankizumab (RZB), a monoclonal antibody targeting interleukin-23 p19, was evaluated for maintenance therapy in patients with moderately to severely active ulcerative colitis (UC) and clinical response to RZB intravenous (IV) induction treatment in a phase 3 double-blind, placebo (PBO)…
Presenter
Speakers
Charité - Universitätsmedizin BerlinMayo Foundation for Medical Education and Research